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Abstract
Objective To evaluate the effect of periodontitis (PD) on glucoregulatory hormones in obesity, never explored so far, a
cross-sectional study was conducted in 110 severely obese, non-diabetic individuals.
Methods We collected clinical periodontal parameters, including probing pocket depth (PPD), bleeding on probing (BOP),
clinical attachment level (CAL). Insulin, glucagon, GLP-1 and GIP were measured after 3 days of standardized diet.
Results Forty-seven subjects had periodontitis (PD+) and 63 did not (PD−). PD+ showed 30.3% of gingival sites with
PPD > 4 mm, 55.2% of BOP sites and a mean CAL loss of 4.1 mm. Compared with PD−, PD+ had higher glucagon (26.60
[25.22] vs 3.93 [7.50] ng/l, p < 0.0001) and GIP levels (10.56 [13.30] vs 6.43 [8.43] pmol/l, p < 0.001), while GLP-1 was
reduced (11.78 [10.07] vs 23.34 [16.80] pmol/l, p < 0.0001). Insulin did not differ. In PD+, after adjustment for con-
founders, PPD was positively related to glucagon (β= 0.424, p= 0.002) and inversely to GLP-1 (β=−0.159, p= 0.044).
Conclusions We describe for the ﬁrst time an impaired incretin axis coupled with a relative hyperglucagonemia in obese
non-diabetic individuals with PD, that might contribute to deteriorate their glucose tolerance and partially explain the higher
risk of diabetes observed in these patients.
Introduction
A bidirectional relationship links metabolic disorders
like type 2 diabetes (T2D) or obesity and periodontitis (PD)
[1]. The common soil between these chronic conditions is
likely to be systemic, low-grade inﬂammation: dental pla-
que releases bioactive products, which in turn stimulate host
responses at the gingival and systemic level, promoting the
release of inﬂammatory cytokines like IL-1β, IL-6, and
TNFα [2, 3]. These mediators are implicated in insulin
resistance, impaired β-cell function, endothelial dysfunc-
tion, driving diabetes onset and the accelerating athero-
sclerosis marking it. Incretin peptides, principally GLP-1
and GIP, regulate islet hormone secretion, glucose con-
centrations, appetite and body weight, and immune func-
tion. A signiﬁcant downregulation of the incretin secretion
is detected in subjects with T2D, and recent studies suggest
important anti-inﬂammatory effects of these molecules [4].
Thus, incretins might represent a pathway potentially
involved in the dysregulation of glucose metabolism in
patients with PD and at high risk of T2D, and the gingival
inﬂammation could potentially exert a detrimental action
also on the incretin axis. Obesity, rather than T2D, might
represent a good model to address such issue, for the rela-
tive preservation of incretin function and, on the other
hand, the high prevalence of periodontal disease [5]. The
present study has been designed to evaluate whether serum
levels of glucoregulatory hormones and incretins might be
inﬂuenced by periodontal condition in obese non-diabetic
individuals.
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Research design and methods
Subjects
One hundred and ten obese (age 48 ± 10 years, 65 females,
BMI 44.6 ± 8.9 kg/m2) patients were sequentially enrolled
over 2015–2016 among participants in screening programs
for periodontal disease. All participants signed an informed
consent. Inclusion criteria were age <60 years, BMI > 35
kg/m2, absence of T2D (excluded by an oral glucose tol-
erance test, OGTT, performed 1 week before the study), no
current smoking habits, no treatment with immunosup-
pressors/antibiotics/anti-inﬂammatory drugs and absence of
systemic inﬂammatory diseases. All patients underwent a
periodontal-screening visit; in those resulted positive to the
periodontal screening record [6], a complete periodontal
examination was performed. After 3 days of standardized
600 kcal diet, blood samples were drawn to measure routine
biochemistry, high sensitivity CRP and plasma levels of
insulin, glucagon, GLP-1 and GIP.
Periodontal clinical parameters
Standard periodontal clinical parameters were registered
using a UNC 15-mm periodontal probe by a calibrated
examiner as previously reported [7]. The examiner recorded
full-mouth pocket probing depth (PPD) and recessions at
six sites per tooth (excluding third molars). Bleeding on
probing (BOP) was recorded as local bleeding present
within 30 s upon probing. Clinical attachment level (CAL)
was calculated as the sum of PPD and gingival recession.
Periodontitis was deﬁned on interproximal CAL loss and
radiographic evidence of bone loss as previously reported
[8]. Periodontitis was stratiﬁed according to the recom-
mendations of the American Academy of Periodontology
[9].
Assays
Plasma insulin was measured by an electro-
chemiluminescence assay on a COBAS e411 (Roche,
Indianapolis, IN, USA). Plasma GLP-1, GIP, and glucagon
were assessed using a Multiplex technique (Millipore Corp,
Billerica, MA, USA and Mercodia AB, Uppsala, SW).
Circulating levels of IL-6, IL-1β, and TNFα were assessed
by commercial ELISA kits (R&D Systems, Minneapolis,
MN, USA) following manufacturer’s instructions.
Statistics
Data were reported as mean ± SD, or median [IQR]. Dif-
ferences between groups were analysed using ANOVA or
Wilcoxon rank sum test for non-normally distributed
variables. Relationships between variables were assessed
using Spearman’s correlation analysis and multiple linear
regression analysis, including stepwise model. Statistics
were performed using JMP®7.0; a p value ≤ 0.05 was con-
sidered signiﬁcant.
Results
Participants were grouped based on the presence (PD+, n
= 47) or absence (PD−, n= 63) of periodontitis. Clinical
characteristics of the study participants are shown in
Table 1. The two groups were balanced for age and gender,
while BMI was signiﬁcantly higher in PD− than and PD+
individuals. Percentage of former smokers was similar
between the groups. Nearly half the population in both
groups had the phenotype of metabolic syndrome. Among
biochemical variables, no differences emerged for fasting
plasma glucose and lipid proﬁle, whereas hsCRP resulted
elevated in both groups, but no differences between groups
were observed. PD+ individuals had a mean number of 26
teeth, 30.3% of gingival sites with PPD > 4 mm, a mean
55.2% of BOP sites and an average CAL loss of 4.1 mm,
indicating a generalized level of tissue loss.







Age (years) 48 ± 7 48 ± 12 0.910
Sex (F/M) 28/19 37/26 0.950
SBP (mmHg) 130.6 ± 18.9 130.1 ± 16.1 0.896
DBP (mm) 85.9 ± 10.6 83.1 ± 11.0 0.245
BMI (kg/m2) 41.4 ± 8.7 47.1 ± 8.3 0.001
Waist (cm) 116.1 ± 10.3 132.1 ± 11.7 0.001
Fasting plasma glucose
(mmol/l)








HOMA-IR 3.38 [2.41] 2.71 [3.58] 0.05
Total cholesterol (mmol/l) 5.29 ± 1.13 5.02 ± 0.96 0.182
Triglycerides (mmol/l) 1.64 ± 0.83 1.61 ± 0.80 0.850
HDL cholesterol (mmol/l) 1.21 ± 0.35 1.26 ± 0.36 0.473
Metabolic syndromea (%) 52 48 0.932
hs CPR (mg/l) 4.31 ± 3.80 3.67 ± 2.62 0.290
IL-6 (pg/ml) 4.45 [2.10] 1.99 [1.34] <0.0001
IL-1β (pg/ml) 3.53 [3.32] 1.99 [1.88] 0.002
TNFα (pg/ml) 2.82 [2.03] 2.03 [1.27] 0.003
aAccording to the IDF Consensus Worldwide Deﬁnition of the
Metabolic Syndrome (2005)
Data are mean ± SD, or median[IQR]
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Glucoregulatory hormones are shown in Fig. 1. Plasma
glucagon concentrations were six-fold higher in PD+
than in PD− subjects, while GLP-1 levels were
markedly reduced. Plasma insulin did not differ
between the groups, while GIP was increased in PD+
individuals.
In the PD+ group, CAL and PPD variables were linearly
correlated with glucagon (r= 0.404, p= 0.003 and r=
0.456, p < 0.001, respectively). For PPD, such relationship
still held at multiple regression analysis including BMI, age,
and gender (β= 0.431, p= 0.002); moreover, when adding
the incretin concentrations in the model, both glucagon (β
= 0.424, p= 0.002) and GLP-1 (β=−0.159, p= 0.044)
resulted associated (full model r2= 0.30). After a stepwise
approach results remained almost unchanged, with gluca-
gon, GLP-1, and BMI explaining about the total variance of
PPD. When comparing different stages of PD [9], glucagon
levels were related with the severity of periodontitis (16.17
± 9.95, 25.25 ± 4.34, 39.24 ± 4.45 ng/l from stages I to III;
p= 0.03).
To better detect the relation between presence of peri-
odontitis and systemic subclinical inﬂammation, we mea-
sured circulating levels of some inﬂammatory cytokines. As
reported in Table 1, IL-6, IL-1β, and TNFα were sig-
niﬁcantly higher in the PD+ group. After modelling data by
a multiple regression analysis, adjusting for sex, BMI, age
and presence of PD, only IL-6 was signiﬁcantly associated
with the presence of PD (β= 0.88, p= 0.04).
Conclusions
This study reports for the ﬁrst time a strong impairment of
incretin axis in obese individuals with severe periodontitis.
An upregulation of glucagon, GLP-1, and GIP has been
previously described in the gingival crevicular ﬂuid of T2D
subjects with periodontitis [10], while circulating levels of
these hormones have never been related to the state of the
gingivae. Our ﬁndings support the notion of a temporal
association between periodontitis and obesity precedent to a
derangement of glucose metabolism (normal OGTT and no
difference in fasting glucose levels between the two
groups), and eventually driving an increased risk of T2D in
obese patients affected by periodontitis. This is further
corroborated by the lower proﬁles of common risk factors
of future T2D (lower BMI and a trend toward higher plasma
glucose). However, our design does not allow inferring
whether weight loss with consequent incretins’ variations
may have a different impact in obese patients with or
without periodontitis.
Intriguingly, CRP seems to mark a similar systemic low-
grade inﬂammation in the two groups, suggesting a primary
Fig. 1 Plasma levels of glucagon, insulin, GLP-1, and GIP in obese non-diabetic individuals without (PD−) and with (PD+) chronic periodontitis.
Data are reported as median and IQR
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involvement of the mouth–gut axis, with a key role of the
periodontitis and the oral inﬂammation as the main deter-
minant of the observed hormone variations.
GLP-1 appears signiﬁcantly reduced in obese patients
with periodontitis. We have attempted to account for the
common confounders like the type of consumed food, able
to inﬂuence gut hormones (our study subjects followed the
same diet for 3 days before the assessment). It is of interest
that raised GLP-1 levels have been reported in critically ill
individuals with a severe systemic inﬂammatory status [11]
or after a major surgical stress [12]; here, diminished GLP-1
levels are observed in humans following a local and
delimited, rather than a systemic, inﬂammatory status.
Looking more in detail to the hormone pattern coupled
with periodontitis, glucagon levels were found to be ele-
vated and correlated with the severity of the disease.
Increased fasting glucagon concentrations may be respon-
sible of the more pronounced insulin resistance [13], as
observed in PD+ individuals according to HOMA-IR. The
slightly higher fasting plasma glucose, likely due to marked
increase in glucagon levels, in association with marginally
raised insulin levels may account for the increased HOMA-
IR in PD+ group. Moreover, this ﬁnding is reinforced by
the fact that inﬂammatory cytokines levels, potentially
associated with insulin resistance, are higher in PD+ group.
In this view, the increased GIP levels deserve attention too,
as they are able to stimulate glucagon secretion; such effect
may help to stabilize glucose levels in healthy individuals,
whilst in T2D and obese subjects these may contribute to
glucose intolerance [14]. The hypothesis of a role of ana-
tomical contiguity between mouth and gut in inﬂuencing
this picture is reinforced by the lack of difference in insulin
levels between obese with and without periodontal disease,
according to previous data in carriers of metabolic syn-
drome [15]. Previous experimental works have shown that
acute inﬂammation promotes GLP-1 secretion [11, 16]; in
the present study, the chronic subclinical inﬂammation,
associated with periodontitis, particularly IL-6, seems to be
linked to an impaired incretin balance, this happens despite
a lower BMI in PD+ individuals. A mere speculation on the
mechanism behind the raised glucagon levels could be the
trophic effect exerted by IL-6 on alpha-cells [17]; regarding
GIP, beside its metabolic effects, it has been recently shown
as it may promote adipose tissue inﬂammation and cytokine
transcripts in humans [18]. In summary, this study shows
for the ﬁrst time a dysregulation of the incretin axis in obese
individuals with periodontitis; we might speculate the
potential role of the oral/gut microbiota in determining this
clinical condition that might accelerate the deterioration of
glucose homoeostasis frequently occurring in these indivi-
duals; a role for subclinical inﬂammation cannot be ruled
out too. If conﬁrmed in large further studies, our ﬁndings
suggest that the incretin axis might represent a novel
important target to prevent the development of T2D in
patients with PD.
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